3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Completed
2
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
14
Gastrointestinal
6
Genitourinary
4
Breast
3
NET
2
Head & Neck
2
Gynecologic
2
Endocrine
2
Dermatologic
2
Conditions
Neuroendocrine Tumors
208
Carcinoid Tumor
26
Neoplasms
22
Pancreatic Neoplasms
16
Gastro-enteropancreatic neuroendocrine tumor
14
Carcinoma, Neuroendocrine
11
Carcinoma
11
Adenoma, Islet Cell
11
Neoplasm Metastasis
10
Colorectal Neoplasms
9
Lung Neoplasms
8
Serotonin Syndrome
7
Prostatic Neoplasms
7
Adenocarcinoma
7
Pheochromocytoma
6
Gastrointestinal Neoplasms
6
Colonic Neoplasms
6
Breast Neoplasms
6
Thyroid Neoplasms
5
Stomach Neoplasms
5
Somatostatinoma
5
Neuroblastoma
5
Melanoma
5
Gastroenteropancreatic Neuroendocrine Tumors
5
Cholangiocarcinoma
5
Carcinoma, Renal Cell
5
Vipoma
4
Sarcoma
4
Rectal Neoplasms
4
Paraganglioma
4
Interventions
pralsetinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Respiratory Tract Neoplasms
×
NET
×
Clear all
NCT03037385
2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2
Completed
590 enrolled
58 charts
3 FDA
NCT00990535
2009-10-07
HIDONET
Federico II University
Phase 2
Completed
28 enrolled